Director Timothy S. Cabral filed a Form 4 with the SEC on November 9, 2026, reporting transactions in Doximity, Inc. (NYSE:DOCS) Class A and Class B Common Stock dated November 5, 2026.
Richard M. Schulze, Chairman Emeritus of Best Buy Co Inc, filed a Form 4 on November 9, 2026, disclosing a change in beneficial ownership of common stock resulting from the appointment of his spouse as trustee of a trust on November 5, 2026.
Carlos Nueno, President, International at Teladoc Health, Inc., filed a Form 4 on November 9, 2026, disclosing the sale of 29,432 shares of common stock on November 6, 2026, under a pre-established Rule 10b5-1 trading plan.
Director and 10% owner Edgar R. Smith III filed a Form 4 with the SEC on November 9, 2026, disclosing a purchase of 5,000 shares of First Guaranty Bancshares, Inc. common stock on November 6, 2026.
A Form 4 filed on November 9, 2026 reports that Beth Bruce Witte, a director of Slide Insurance Holdings, Inc. (NASDAQ:SLDE), sold 25,000 shares of common stock on November 5, 2026 through the Beth W. Bruce Witte Family 1992 Trust.
Juan Andres, Chief Operating Officer of Moderna, Inc., filed a Form 4 on November 9, 2026, disclosing the acquisition of stock options and restricted stock units on November 5, 2026 under NASDAQ:MRNA.
Director Joel Ackerman of Champions Oncology, Inc. filed a statement of changes in beneficial ownership on November 9, 2026, reporting the acquisition of options to purchase 31,216 shares of common stock on November 5, 2026.
Carl Russo, a director and 10% owner of Calix, Inc. (NYSE:CALX), filed a Form 4 on November 9, 2026, disclosing the sale of 75,000 shares of common stock on November 6, 2026, pursuant to a Rule 10b5-1 trading plan.
Director and 10% owner Scott R. Tobin filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of stock options to purchase common stock of Champions Oncology, Inc. (NASDAQ:CSBR), with the earliest transaction date of November 5, 2026.
Director Daniel Newman Mendelson filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of options to purchase common stock of Champions Oncology, Inc. (NASDAQ:CSBR), with the earliest transaction date of November 5, 2026.